Haiyan Li is a highly motivated scientist with extensive expertise in immuno-oncology and preclinical pharmacology. Currently serving as a Principal Research Scientist II at AbbVie, they lead the pharmacology strategy in the immuno-oncology team, focusing on CRISPR-mediated early discovery and the development of novel therapeutics. Haiyan has previously held postdoctoral positions at The Johns Hopkins University School of Medicine and UT MD Anderson Cancer Center, where they explored mechanisms in immune cell development and pathogenesis. They also contributed as an Assistant Professor and Instructor, investigating the intricacies of immunotherapy and immune response to tumor microenvironments. Haiyan holds a PhD in Immunology from Memorial University of Newfoundland and is pursuing a Doctor of Medicine degree at Peking University Health Science Center.
This person is not in any teams
This person is not in any offices